Tarsus Pharmaceuticals, Inc. (TARS)Healthcare | Biotechnology | Irvine, United States | NasdaqGS
71.76 USD
-0.16
(-0.222%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 71.76 |
Hot Take ↕ | Aug. 22, 2026, 2:08 a.m. EDT
The narrative here is a classic biotech turnaround story fueled by asymmetric option positioning. Fundamentally, the company is showing signs of life with a 69% revenue surge and a fortress-like balance sheet (3.2x current ratio, minimal debt), yet it remains unprofitable with negative operating margins. This disconnect creates a high-risk, high-reward profile. The stock has rallied 135% over the last four years, validating the long-term thesis, but the recent price action shows the market is waiting for a specific catalyst to bridge the gap between current valuations and the analyst mean target of nearly $95. The options market is screaming for volatility; traders are buying cheap lottery tickets at the 95 strike while selling protection at the 60 level, betting that the next earnings report or partnership announcement will trigger a sharp move. For investors, this is a speculative play on execution risk; the business quality is improving, but the path to profitability is still obscured by R&D burn. It is not a core holding yet, but the setup for a momentum-driven breakout is forming. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.060891 |
| AutoETS | 0.066803 |
| AutoARIMA | 0.066809 |
| AutoTheta | 0.112001 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 0.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.380 |
| Excess Kurtosis | -0.19 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 25.614 |
| Revenue per Share | 14.121 |
| Market Cap | 3,149,043,968 |
| Forward P/E | 30.86 |
| Beta | 0.51 |
| Profit Margins | -7.66% |
| Website | https://tarsusrx.com |
As of Aug. 22, 2026, 2:08 a.m. EDT: Speculators are positioning for a volatile rebound rather than a steady grind higher. Call volume is heavily skewed toward out-of-the-money strikes (95 and 90) for the January 2027 expiration, suggesting a bet on a significant gap-up event. Conversely, put writers are accumulating massive open interest at the 57.5 and 60 strikes for October 2026, creating a 'pin risk' zone where sellers hope to profit if the stock stalls. The disparity in implied volatility—where deep OTM calls trade at standard levels while deep ITM puts are virtually non-existent—indicates traders expect the downside to be capped by the current price floor, but the upside potential to be explosive if catalysts like the iRenix talks or Phase 3 data materialize.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.22478235 |
| Address1 | 17,700 Laguna Canyon Road |
| Address2 | Floor 4 |
| All Time High | 85.25 |
| All Time Low | 10.8 |
| Ask | 90.76 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 615,780 |
| Average Daily Volume3 Month | 946,273 |
| Average Volume | 946,273 |
| Average Volume10Days | 615,780 |
| Beta | 0.512 |
| Bid | 71.46 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 8.111 |
| City | Irvine |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 71.76 |
| Current Ratio | 3.198 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 72.03 |
| Day Low | 70.73 |
| Debt To Equity | 25.614 |
| Display Name | Tarsus Pharmaceuticals |
| Earnings Call Timestamp End | 1,786,017,600 |
| Earnings Call Timestamp Start | 1,786,017,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -46,195,000 |
| Ebitda Margins | -0.07619 |
| Enterprise To Ebitda | -60.356 |
| Enterprise To Revenue | 4.598 |
| Enterprise Value | 2,788,164,864 |
| Eps Current Year | -2.132 |
| Eps Forward | 2.325 |
| Eps Trailing Twelve Months | -1.07 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 64.3476 |
| Fifty Day Average Change | 7.4123993 |
| Fifty Day Average Change Percent | 0.11519309 |
| Fifty Two Week Change Percent | 22.478235 |
| Fifty Two Week High | 85.25 |
| Fifty Two Week High Change | -13.489998 |
| Fifty Two Week High Change Percent | -0.15824044 |
| Fifty Two Week Low | 48.2 |
| Fifty Two Week Low Change | 23.560001 |
| Fifty Two Week Low Change Percent | 0.4887967 |
| Fifty Two Week Range | 48.2 - 85.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,602,855,000,000 |
| Float Shares | 32,679,667 |
| Forward Eps | 2.325 |
| Forward P E | 30.864517 |
| Free Cashflow | 67,467,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 370 |
| Fullday Change | -0.159996 |
| Fullday Change Percent | -0.222464 |
| Fullday Price | 71.76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.82672 |
| Gross Profits | 501,264,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02865 |
| Held Percent Institutions | 1.06074 |
| Implied Shares Outstanding | 43,882,996 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. |
| Long Name | Tarsus Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 3,149,043,968 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_650383665 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -46,476,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,159,575,712 |
| Number Of Analyst Opinions | 7 |
| Open | 71.52 |
| Operating Cashflow | 74,158,000 |
| Operating Margins | -0.11447 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 949 418 1801 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 71.76 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 71.92 |
| Price Eps Current Year | -33.65854 |
| Price Hint | 2 |
| Price To Book | 8.847244 |
| Price To Sales Trailing12 Months | 5.1936054 |
| Profit Margins | -0.07665 |
| Quick Ratio | 3.118 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.159996 |
| Regular Market Change Percent | -0.222464 |
| Regular Market Day High | 72.03 |
| Regular Market Day Low | 70.73 |
| Regular Market Day Range | 70.73 - 72.03 |
| Regular Market Open | 71.52 |
| Regular Market Previous Close | 71.92 |
| Regular Market Price | 71.76 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 615,723 |
| Return On Assets | -0.05485 |
| Return On Equity | -0.13683 |
| Revenue Growth | 0.694 |
| Revenue Per Share | 14.121 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 43,882,996 |
| Shares Percent Shares Out | 0.1367 |
| Shares Short | 5,997,475 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,783,063 |
| Short Name | Tarsus Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1412 |
| Short Ratio | 6.31 |
| Source Interval | 15 |
| State | CA |
| Symbol | TARS |
| Target High Price | 104.0 |
| Target Low Price | 84.0 |
| Target Mean Price | 94.85714 |
| Target Median Price | 99.0 |
| Total Cash | 449,689,984 |
| Total Cash Per Share | 10.247 |
| Total Debt | 88,811,000 |
| Total Revenue | 606,331,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 68.56328 |
| Two Hundred Day Average Change | 3.196724 |
| Two Hundred Day Average Change Percent | 0.046624433 |
| Type Disp | Equity |
| Volume | 615,723 |
| Website | https://tarsusrx.com |
| Zip | 92,618 |